Alpha DaRT™ achieves a 78.6% complete response rate in management of challenging squamous cell carcinoma tumors. Tel Aviv, Israel, November 26, 2019 – Alpha Tau Medical is pleased to announce the publication of the results of its first clinical trial of Alpha DaRT™, a novel alpha radiation cancer treatment, in the International Journal of Radiation Oncology, Biology, and Physics, the official journal of the American Society for Radiation Oncology. The objectives of the trial,